Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Conduit Pharmaceuticals (Nasdaq: CDT) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The company's Founder and CEO, Dr. David Tapolczay, will deliver a virtual presentation available on-demand starting September 9th at 7:00 am ET/12:00 pm BST.

Dr. Tapolczay will also be available for in-person, one-on-one investor meetings throughout the conference at the Lotte New York Palace Hotel. Interested parties can register for the presentation via H.C. Wainwright's website. Additionally, a webcast of the presentation will be accessible on Conduit's company website in the Events section.

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26^th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9^th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay will also be available for in-person, one-on-one investor meetings throughout the conference being held at Lotte New York Palace Hotel, 455 Madison Avenue, New York City.

To view Dr. Tapolczay’s presentation, please use the following link to register via H.C. Wainwright’s website (www.hcwevents.com/annualconference). A webcast of the presentation will also be available on the Company Events section of the Company’s website at (www.conduitpharma.com).

About Conduit Pharmaceuticals

Conduit is a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets and then seeks an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks as identified in filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors
Bill Begien
Conduit Pharmaceuticals Inc.
bb@conduitpharma.com

FAQ

When is Conduit Pharmaceuticals (CDT) presenting at the H.C. Wainwright Global Investment Conference?

Conduit Pharmaceuticals (CDT) will have an on-demand virtual presentation available starting September 9, 2024, at 7:00 am ET/12:00 pm BST as part of the H.C. Wainwright 26th Annual Global Investment Conference.

Who will be presenting for Conduit Pharmaceuticals (CDT) at the H.C. Wainwright conference?

Dr. David Tapolczay, Founder and CEO of Conduit Pharmaceuticals (CDT), will be giving the virtual presentation and will be available for in-person investor meetings during the conference.

Where can investors view Conduit Pharmaceuticals' (CDT) presentation from the H.C. Wainwright conference?

Investors can view the presentation by registering on H.C. Wainwright's website (www.hcwevents.com/annualconference) or by accessing the webcast on Conduit Pharmaceuticals' website (www.conduitpharma.com) in the Company Events section.

What are the dates for the H.C. Wainwright Global Investment Conference featuring Conduit Pharmaceuticals (CDT)?

The H.C. Wainwright 26th Annual Global Investment Conference, featuring Conduit Pharmaceuticals (CDT), is being held from September 9-11, 2024.

Where is the H.C. Wainwright conference with Conduit Pharmaceuticals (CDT) taking place?

The in-person component of the H.C. Wainwright 26th Annual Global Investment Conference, including one-on-one meetings with Conduit Pharmaceuticals (CDT), is being held at the Lotte New York Palace Hotel, 455 Madison Avenue, New York City.